Check for updates

#### **OPEN ACCESS**

EDITED BY Yu Zhang, Chinese Academy of Agricultural Sciences, China

REVIEWED BY Mahder Teffera, Canadian Food Inspection Agency (CFIA), Canada Zhou Yanlong, Chinese Academy of Agricultural Sciences, China

\*CORRESPONDENCE Min Zheng ⊠ zhgmn26@163.com Chuanhuo Hu ⊠ hch64815@gxu.edu.cn Yanjuan Liao ⊠ liaoyanjuan\_gxun@163.com

<sup>†</sup>These authors have contributed equally to this work and share first authorship

RECEIVED 03 May 2025 ACCEPTED 19 June 2025 PUBLISHED 07 July 2025

#### CITATION

Xin J, Shi Y, Du Q, Liao Y, Zhao Z, Bi J, Peng J, Cheng S, Hu C and Zheng M (2025) Exploring the function and pathogenicity of Goatpox virus N1L gene using recombinant vaccinia virus Tiantan strain. *Front. Vet. Sci.* 12:1622506. doi: 10.3389/fvets.2025.1622506

#### COPYRIGHT

© 2025 Xin, Shi, Du, Liao, Zhao, Bi, Peng, Cheng, Hu and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

### Exploring the function and pathogenicity of Goatpox virus N1L gene using recombinant vaccinia virus Tiantan strain

Jialiang Xin<sup>1,2†</sup>, Yaqi Shi<sup>3†</sup>, Qian Du<sup>2,4†</sup>, Yanjuan Liao<sup>5</sup>\*, Zhongyi Zhao<sup>2</sup>, Jingshan Bi<sup>2</sup>, Jiuqing Peng<sup>2,4</sup>, Sheng Cheng<sup>1</sup>, Chuanhuo Hu<sup>4</sup>\* and Min Zheng<sup>2</sup>\*

<sup>1</sup>Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, China, <sup>2</sup>Guangxi Center for Animal Disease Control and Prevention, Nanning, China, <sup>3</sup>Yunnan Animal Health Supervision Institute, Kunming, China, <sup>4</sup>College of Animal Science and Technology, Guangxi University, Nanning, China, <sup>5</sup>Guangxi Key Laboratory of Polysaccharide Materials and Modification, School of Marine Sciences and Biotechnology, Guangxi Minzu University, Nanning, China

The N1L gene is a well-characterized virulence factor in the poxvirus family; however, its functional role in Goatpox virus (GTPV) remains poorly understood. To elucidate the biological significance of the GTPV N1L gene (gN1L), we constructed three recombinant vaccinia virus Tiantan strain (rVVT) using homologous recombination: rVVT- $\Delta v$ N1L (deletion of VVT N1L), rVVT-vN1Lr (insertion of enhanced green fluorescent protein, EGFP), and rVVT-gN1L (substitution with gN1L). The biological properties of these recombinant strains were systematically compared with those of wild-type VVT to evaluate the functional role of gN1L. Bioinformatics analysis revealed that the gN1L-encoded protein shares 26.80% homology and 45.10% similarity with the VVT N1L (vN1L)-encoded protein. Notably, the gN1 protein was predicted to be structurally stable, whereas the vN1 protein was classified as unstable. Growth curve assays demonstrated that gN1L significantly enhances VVT replication in BHK-21, HeLa, and PK-15 cells. RNA-seq analysis further suggested that this enhancement is potentially mediated through the PI3K/AKT signaling pathway. In vitro and in vivo virulence assays indicated that gN1L increases VVT virulence by up to 133-fold, representing a 7.5-fold greater effect compared to vN1L. Additionally, viral load measurements in host tissues revealed that gN1L facilitates VVT traversal across the blood-brain barrier by enhancing its ability to infect glial and endothelial cells. Collectively, these findings provide novel insights into the functional role of gN1L and offer valuable implications for the development of safer attenuated vaccines against GTPV.

#### KEYWORDS

Goatpox virus, N1L, vaccinia virus, Tian Tan strain, biological functions

### **1** Introduction

Goatpox virus (GTPV), sheeppox virus (SPPV), and lumpy skin disease virus (LSDV) belong to the *Capripoxvirus* genus within the *Poxviridae* family. These enveloped, brick-shaped viruses measure approximately  $294 \pm 20$  nm in length and  $262 \pm 22$  nm in width, and possess large double-stranded DNA genomes (1–3). GTPV and SPPV cause acute, highly contagious diseases in goats and sheep, characterized by fever, skin nodules, respiratory and gastrointestinal lesions, and lymphadenopathy (4). LSDV primarily infects cattle, causing skin nodules and significant economic losses, including reduced milk production, weight loss,

abortion, and infertility (5–7). These viruses are globally distributed and pose substantial economic threats due to the high costs of outbreak control and eradication efforts (8–11). Consequently, they are classified as notifiable diseases by the World Organization for Animal Health (WOAH) (4, 12, 13).

Currently, no effective antiviral drugs are available for infections caused by GTPV, SPPV, or LSDV. Vaccination remains the primary strategy for prevention and control. In China, an attenuated vaccine based on the GTPV-AV41 strain is widely used to protect goats against GTPV and SPPV and has also been employed to prevent LSDV outbreaks due to the 96% genetic similarity between GTPV and LSDV. However, this vaccine has limitations, as some vaccinated animals still develop adverse symptoms, including localized lesions, severe secondary infections, and even death (14). These challenges highlight the urgent need for safer and more effective vaccines. A critical step is to deepen our understanding of GTPV gene functions to inform the rational design of next-generation vaccines. However, progress has been hindered by the virus's narrow host range and the requirement for Biosafety Level 3 (BSL-3) laboratory conditions. As a result, much of our current knowledge about GTPV gene function is extrapolated from studies on Vaccinia virus (VACV), despite the fact that GTPV and VACV belong to different genera. This reliance on VACV as a model raises questions about the accuracy of our understanding of GTPV-specific gene functions, underscoring the need for direct experimental investigations.

The N1L gene is a well-documented virulence factor within the poxvirus family. Studies have shown that VACV lacking the N1L gene exhibits significantly reduced pathogenicity compared to the wild-type virus when administered via intracranial injection in mice (15). Similarly, the N1L gene in Ectromelia virus (ECTV) plays a critical role in viral pathogenicity, with N1L-deficient ECTV demonstrating a 1,000-fold reduction in virulence compared to the wild-type virus in subcutaneous mice models (16). Despite its established importance in other poxviruses, the N1L gene in GTPV remains poorly characterized. To date, it is only known that the GTPV N1L gene is encoded by the 135 open reading frame and can inhibit the TNF- $\alpha$ - or IL-1 $\beta$ -induced NF- $\kappa$ B pathway (17). However, given that virulence proteins often interact with host cells through multiple mechanisms and pathways, further research is needed to fully elucidate the biological functions of the GTPV N1L (gn1L) gene.

The Tiantan strain of vaccinia virus (VVT) was originally isolated in China in 1926 (18, 19). Through successive passages in monkeys, rabbits, and calves, this strain has been extensively attenuated, resulting in a highly attenuated phenotype with significantly reduced virulence compared to the Western Reserve (WR) strain (20–22). In this study, we constructed a recombinant Vaccinia virus Tiantan strain (rVVT) expressing the gN1L gene using homologous recombination. To comprehensively investigate the biological functions of the gN1L gene, we employed a multidisciplinary approach, including bioinformatics analysis, a series of *in vitro* and *in vivo* experiments, and transcriptomic profiling.

### 2 Materials and methods

#### 2.1 Cells, viruses, and animals

BHK-21, HeLa, and PK-15 cells were obtained from the China Center for Type Culture Collection. The VVT strain (GenBank:

AF095689) was sourced from the Institute of Virology, Changchun Veterinary Research Institute. Five-week-old male BALB/c mice were purchased from Chengdu Dashuo Experimental Animal Co., Ltd.

### 2.2 Stability analysis of GTPV N1 protein

The GTPV N1 protein (AGZ95457.1) and VVT N1 protein (AAF33880.1) sequences were downloaded from the National Center for Biotechnology Information (NCBI) website.<sup>1</sup> Sequence alignment was performed using VectorBuilder,<sup>2</sup> Tand protein stability was assessed using ExPASy ProtParam.<sup>3</sup>

### 2.3 Construction of recombinant viruses

Three recombinant VVT viruses (rVVT) were constructed via homologous recombination: rVVT- $\Delta$ vN1L (lacking vN1L, containing EGFP), rVVT-vN1Lr (carrying EGFP), and rVVTgN1L (deleting vN1L, incorporating gN1L and EGFP). Viral purity was confirmed by RT-qPCR. All four strains were propagated in BHK-21 cells, and their copy numbers and TCID<sub>50</sub> values were determined (23). Primer sequences are listed in Supplementary Table 1. Relative RNA abundance was quantified using the 2<sup>- $\Delta\Delta$ Ct</sup> method.

### 2.4 Growth characteristics and toxicity evaluation of recombinant viruses *in vitro*

The replication capabilities of the rVVTs were analyzed using growth curves. Cells were infected with rVVTs at  $4.23 \times 10^3$  copies (0.01 MOI) in six-well plates. DNA levels were measured by qPCR at 2, 4, 6, 8, 10, 12, 24, 36, 48, and 72 h post-infection. Cell viability was assessed using the CCK-8 assay at 12, 24, 48, and 72 h post-infection in 96-well plates. Cytotoxicity was further evaluated at 24 h post-infection in 12-well plates at  $4.23 \times 10^4$  copies, with crystal violet staining.

# 2.5 Evaluation of toxicity of recombinant viruses *in vivo*

BALB/c mice were divided into 25 groups based on intracranial injection doses (Figure 1A). The 50% lethal infectious dose (LD<sub>50</sub>) was determined (23). Pathological analyses were conducted on brain tissues at 10 days post-inoculation ( $4.23 \times 10^4$  to  $4.23 \times 10^9$  copies), and cytokine levels (IL-6, TNF- $\alpha$ , IL-1 $\beta$ ) were measured. Viral loads in organs were assessed by RT-qPCR. Primers sequences are shown in Supplementary Table 1. The relative RNA abundance was quantified using the  $2-\Delta^{\Delta \Delta Ct}$  method.

2 https://www.vectorbuilder.cn/tool/sequence-alignment.html

<sup>1</sup> https://www.ncbi.nlm.nih.gov

<sup>3</sup> http://web.expasy.org/protparam/



2.6 RNA sequencing

Brain tissue samples were collected from each group of mice, with three pieces of tissue pooled per group to ensure sufficient material for analysis. The pooled brain tissue samples were then sent to Nanning Guotuo Biotechnology Co., Ltd. for total RNA extraction, library construction, and RNA-seq. Differential gene expression DEGs was analyzed from brain samples, with  $|log2FC| \ge 1$  and a *p*-value < 0.05.

The identified DEGs were analyzed for protein–protein interactions (PPIs) using the STRING database.<sup>4</sup> To gain insights into the biological functions and pathways associated with the DEGs, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using the DAVID Bioinformatics Resources.<sup>5</sup> A *p*-value < 0.05 was considered statistically significant for GO functional and KEGG pathway enrichment.

### 2.7 Protein–protein interaction affinity analysis

To verify the accuracy of transcriptome analysis results, we employed RT-qPCR to determine gene expression levels. Primers sequences are shown in Supplementary Table 1. The three-dimensional structures of the gN1 and vN1 proteins were constructed using

SwissModel.<sup>6</sup> Subsequently, the protein structures of Clic4, Gfap, and Himox1 were retrieved from the RCSB PDB database.<sup>7</sup> ClusPro<sup>8</sup> was then utilized to analyze the interactions between the two viral proteins and their associated proteins.

#### 2.8 Statistical analysis

Data were analyzed using GraphPad Prism 9.5, with significance assessed by unpaired t-tests for two-group comparisons or one-way ANOVA for multiple groups (p < 0.05).

### **3** Results

### 3.1 The gN1 protein exhibits greater stability vN1 protein

Sequence alignment revealed that gN1 and vN1 proteins shared 26.80% identity and 45.10% similarity (Figure 2A). The amino acid compositions of these proteins were distinct, with gN1 exhibiting greater stability than vN1 (Figures 2B,C). Structural differences between the three rVVT viruses and the wild type are depicted in Figure 2D. Recombinant viruses were purified via successive passages and viral fluorescent plaque selection (Figure 2E). RT-qPCR was used to

<sup>4</sup> https://string-db.org/

<sup>5</sup> https://david.ncifcrf.gov

<sup>6</sup> https://swissmodel.expasy.org

<sup>7</sup> https://www.rcsb.org

<sup>8</sup> https://cluspro.org



identify the purified viruses. As shown in Figure 3C, rVVT-gN1L amplified gN1L but not vN1L, whereas rVVT-vN1Lr and rVVT- $\Delta$ N1L amplified vN1L but not gN1L. The TCID<sub>50</sub> and viral copy number determination processes are illustrated in Figure 2F. The TCID<sub>50</sub> values were similar among all four viruses (Figure 2G), but rVVT-gN1L had a significantly higher viral copy number (Figure 2H).

# 3.2 The gN1L gene enhances VVT replication and cytotoxicity *in vitro*

To assess the impact of gN1L on viral proliferation and cytotoxicity, *in vitro* experiments were performed (Figure 3A). Growth curve analysis showed that all four viruses exhibited similar growth patterns in the three cell types tested (Figure 3B). However, rVVT-gN1L had a significantly higher growth rate compared to the other three viruses, which had comparable growth rates (Figure 3C). Crystal violet staining revealed that plaque formation was essentially identical among the four viruses in different cells (Figure 3D), suggesting that the growth advantage of rVVT-gN1L was not significantly greater than that of the other viruses. Cytotoxicity assays indicated that rVVT-gN1L induced the highest level of cytotoxicity, while rVVT- $\Delta$ vN1L exhibited the lowest (Figure 3E). rVVT-vN1Lr and VVT displayed similar cytotoxicity levels (Figure 3E).

# 3.3 The gN1L gene enhances VVT toxicity in BALB/c mice

To evaluate the pathogenicity of the recombinant viruses, BALB/c mice were intracranially inoculated with different doses of each virus,

and their survival rates and pathological indices were monitored (Figure 4A). Except for the DMEM control group, all infected mice exhibited neurological symptoms, including fatigue, convulsions, stiffness, and hair loss, starting on the first day post-inoculation. Mice inoculated with rVVT-gN1L had the earliest mortality and the highest mortality rate (Figure 4B). The median lethal doses (LD<sub>50</sub>) for rVVT-gN1L, rVVT-vN1Lr, VVT, and rVVT- $\Delta$ vN1L were calculated as  $10^{-3.25}/0.1$  mL ( $2.38 \times 10^5$  copies),  $10^{-2.375}/0.1$  mL ( $1.78 \times 10^6$  copies),  $10^{-2.375}/0.1$  mL ( $3.17 \times 10^7$  copies), respectively.

Pathological examination showed that brain tissues from mice inoculated with  $4.23 \times 10^5$  of rVVT-gN1L exhibited the most severe vacuolar degeneration, while those from rVVT- $\Delta$ vN1L showed the least (Figures 4C,D). Viral load analysis revealed that rVVT-gN1L was detectable in all organs, though the brain had the lowest viral load (Figure 4E). In contrast, rVVT- $\Delta$ vN1L had the highest concentration in the brain, with only trace amounts in the liver. rVVT-vN1Lr and VVT had comparable viral loads in brain tissue and were also present in the liver and lungs (Figure 4E). RT-qPCR and ELISA analysis showed that the levels of inflammatory factors in the brains of mice infected with rVVT-gN1L were significantly higher than those in other groups (Figure 4F).

# 3.4 The enhanced pathogenicity of gN1L-associated VVT is linked to the PI3K/ AKT signaling pathway

The RNA-seq and analysis workflow are shown in Figure 1A. Compared to the control group, the rVVT-gN1L group had 30 upregulated and 31 downregulated genes (Figure 1B). The



rVVT-vN1Lr group had 45 upregulated and 16 downregulated genes (Figure 1C), while the rVVT- $\Delta$ N1L group had 23 upregulated and 17 downregulated genes (Figure 1D). A heatmap was constructed to highlight 61 differentially expressed genes associated with rVVTgN1L (Figure 1E). Venn analysis identified target genes associated with gN1L and vN1L. gN1L was responsible for the upregulation of 24 genes and the downregulation of 19 genes (Figures 1F,G), while vN1L led to the upregulation of 42 genes and the downregulation of 7 genes (Figures 1F,G). KEGG pathway enrichment analysis indicated that gN1L-related genes were primarily enriched in the PI3K/AKT signaling pathway, estrogen signaling pathway, and cAMP signaling pathway (Figure 1H). In contrast, vN1L-related genes were associated with GnRH secretion, cardiac muscle contraction, and the HIF-1 signaling pathway (Figure 11). RT-qPCR validation confirmed the reliability of the transcriptomic data, with expression trends of Col4a1, Spp1, Gng7, and Igf2 consistent with the heatmap (Figure 1J).

# 3.5 gN1L promotes VVT crossing of the host blood-brain barrier

To identify genes associated with the blood-brain barrier (BBB), we screened for iterms related to endothelial and glial cells, critical components of the BBB, using Gene Ontology (GO) biological process (BP) annotation (Figures 5A,B). Venn analysis revealed that gN1L-related biological processes included those of vN1L (Figures 5C,D), with significant overlap between the two (Figure 5E).

To assess the structural quality of the encoded proteins, we utilized two evaluation metrics: GMQE (Global Model Quality Estimation) and QMEANDisCo Global. GMQE is an index that evaluates the quality of protein structural models, scored on a scale of 0 to 1, with higher values indicating greater model accuracy (24). QMEANDisCo Global, an extension of QMEAN, evaluates the global quality of protein structure models by calculating the average QMEANDisCo score for each residue (25). Scores range from 0 to 1, with values > 0.6 considered indicative of high-quality models. The three-dimensional structures of the gN1L- and vN1L-encoded proteins were evaluated using GMQE and QMEANDisCo Global metrics (Figure 5F). The GMQE scores for the gN1 and vN1 protein models were 0.57 and 0.89, respectively, while the QMEANDisCo Global scores were  $0.62 \pm 0.07$  and  $0.83 \pm 0.06$ , respectively, confirming that the models constructed in this study are of good quality. Compared to the vN1 protein, the gN1 protein formed stronger interactions with the target proteins, as indicated by the higher number of MEMBERS (Figure 5G). MEMBERS refers to the number of similar docking conformations within a cluster, with a larger number indicating greater reliability of the results. RT-qPCR analysis showed that gN1 downregulated the mRNA levels of key genes, including Homx1, Gfap, Vim, Tcf7l2, and Clic4 (Figure 5H).

### 4 Discussion

Attenuated goatpox virus (GTPV) vaccines are crucial for protecting livestock against GTPV, sheeppox virus (SPPV), and lumpy



skin disease virus (LSDV) infections (26, 27). However, the severe immune reactions they can induce highlight the urgent need for safer and more effective vaccine alternatives. A deeper understanding of GTPV gene functions and their interactions with host organisms is essential for developing next-generation vaccines with improved safety profiles through rational modification of the viral genome. However, these inferences may not accurately reflect the biological role of gN1L in GTPV. In this study, we used bioinformatics tools to analyze the gN1 and vN1L protein sequences. Our results revealed that the amino acid identity between gN1 and vN1L is only 26.80%, with a similarity of 45.10%. These findings are consistent with a previous study reporting a 20% identity between the N1 protein sequences of VACV strain WR and GTPV AV41 (17), suggesting that the functional roles of these two proteins are not entirely overlapping. Additionally, we observed that the gN1 protein is more stable than the vN1 protein. Given that viral replication and pathogenicity are significantly influenced by the stability and functionality of encoded proteins (28, 29), these findings suggest that gN1 likely plays a more substantial role in enhancing viral pathogenicity within the host.

To investigate the biological function of the gN1 protein, we inserted the gN1L gene into the vaccinia virus Tiantan (VVT) strain. This approach was chosen for two main reasons: first, VVT can be studied under standard laboratory conditions; second, its ability to infect mice significantly reduces experimental costs. Moreover, both VVT and GTPV belong to the poxvirus family, and despite substantial differences in their N1L genes, VVT and GTPV cause very similar symptoms in the host due to many homologous genes between them, such as E4L (30), A4L (31), and A27L (32). These homologous genes result in similar clinical symptoms between the two viruses. By introducing gN1L into VVT, we were able to simulate the gene's function more accurately by comparing the biological properties of the virus before and after modification.

An intriguing observation emerged during the quantification of viral copy numbers and TCID<sub>50</sub> values in vitro. While the TCID<sub>50</sub> values for all viruses were similar, the copy number of the virus carrying the gN1L gene was significantly higher than that of the other groups. To further explore the potential role of gN1L in promoting viral replication, we employed an absolute fluorescence quantification method to measure viral copy numbers. After re-inoculating the viruses at a uniform copy number concentration across different cell types, we found that rVVT-gN1L exhibited the highest growth rate, while the growth rates of rVVT-vN1Lr, rVVT-ΔvN1L, and VVT were comparable. This suggests that gN1L enhances VVT proliferation, a finding that contrasts with previous reports indicating that gN1L does not facilitate viral replication (17). This discrepancy likely stems from methodological differences. Previous studies relied on the TCID<sub>50</sub> method to assess viral growth characteristics (17). While TCID<sub>50</sub> measures the presence or absence of cytopathic effects (CPE), it does not provide an absolute count of viral particles, as CPE intensity is only loosely correlated with virion quantity (33). In contrast, RT-qPCR offers a more direct and accurate measurement of viral load, enabling precise quantification of viral replication dynamics. In this study,



we inoculated three cell types with a uniform copy number of four viruses and measured viral copy numbers in the supernatant at various time points. The results demonstrated that rVVT-gN1L had a higher growth rate in all cell types compared to the other viruses, which exhibited similar growth rates. This confirms that the gN1L gene enhances VVT proliferation, whereas the vN1L gene is non-essential for VVT replication, consistent with prior findings (34). The PI3K/AKT signaling pathway has been implicated in poxvirus replication. When mature VVT particles bind to host cell surface receptors via viral membrane proteins, integrin ß1 mediates the activation of PI3K/AKT, facilitating viral endocytosis (35). Furthermore, PI3K/AKT is involved in intracellular viral morphogenesis. For instance, the PI3K inhibitor LY294002 has been shown to stall the immature-virion/immature-virion-with-nucleoid stage in the morphogenic cycles of VACV and CPXV (36). In our transcriptomic analysis, KEGG pathway enrichment revealed that gN1L is associated with the PI3K/AKT signaling pathway, with key enriched genes including Col4a1, Spp1, Gng7, and Igf2. RT-qPCR validation confirmed that the expression trends of these genes aligned with the transcriptomic data. Based on these findings, we hypothesize that gN1L promotes VVT replication by activating the PI3K/AKT signaling pathway.

The gN1 protein not only enhances VVT replication but also significantly amplifies its cytotoxicity. To evaluate the toxicitypromoting effects of gN1L, we conducted both *in vitro* and *in vivo* studies. *In vitro* experiments demonstrated that, at comparable viral copy numbers, rVVT-gN1L exhibited significantly higher cytotoxicity in all three cell types compared to the other viral groups. The cytotoxicity levels of rVVT-vN1Lr and VVT were similar, while rVVT-ΔvN1L showed the lowest toxicity. In vivo studies further corroborated these findings, as comparisons of median LD50 values revealed that the presence of gN1L in VVT (with vN1L deleted) increased its toxicity in mice by approximately 133.35-fold, which is about 7.50 times greater than the toxicity observed with vN1L in VVT (with vN1L deleted). These results unequivocally demonstrate that gN1L exerts a significantly stronger promotional effect on VVT cytotoxicity compared to vN1L. Our analysis of viral loads in mice organs revealed a notable pattern. The brain viral load of rVVT-ΔvN1L was significantly higher than that of other groups, while rVVT-gN1L exhibited the lowest brain viral load, despite its robust growth rate in cell cultures. In contrast, rVVT-gN1L was detected in multiple organs, including the heart, lungs, spleen, and liver, whereas rVVT-vN1Lr and VVT were mainly found in the liver and lungs, and rVVT- $\Delta$ vN1L was limited to the brain and liver. These findings suggest that the gN1L gene may enhance VVT's ability to cross the blood-brain barrier (BBB). The BBB, composed of glial cells (astrocytes and microglia), pericytes, and vascular endothelial cells, acts as a critical barrier to prevent pathogens from entering the brain (37, 38). Our transcriptomic analysis showed that gN1L is more involved in biological processes related to glial and vascular endothelial cells than vN1L. Key associated genes included Clic4, Gfap, and Hmox1. Protein-protein docking and RT-qPCR results further validated these observations, confirming their reliability.

### **5** Conclusion

In conclusion, this study demonstrates that the virulence of gN1L against viruses is significantly enhanced. While N1L promotes viral proliferation, this effect does not lead to a qualitative change in viral replication within the host. These findings suggest that N1L may serve as a potential target for the development of attenuated vaccines, offering new insights for optimizing vaccine design strategies.

### Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary material.

### **Ethical statements**

Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used. The animal study was approved by Sichuan Agricultural University Animal Ethical and Welfare Committee (Approval No. 20250029). The study was conducted in accordance with the local legislation and institutional requirements.

#### Author contributions

JX: Writing – review & editing, Software, Writing – original draft. YS: Methodology, Writing – original draft. QD: Writing – original draft, Methodology. YL: Supervision, Writing – review & editing, Writing – original draft. ZZ: Conceptualization, Writing – original draft, Writing – review & editing. JB: Writing – original draft, Writing – review & editing, Conceptualization. JP: Writing – review & editing, Conceptualization, Writing – original draft, Supervision, Writing – review & editing, Crt: Supervision, Writing – review & editing, Writing – original draft. MZ: Writing – original draft, Writing – review & editing, Supervision.

### References

1. Kitching RP, Smale C. Comparison of the external dimensions of capripoxvirus isolates. *Res Vet Sci.* (1986) 41:425–7. doi: 10.1016/S0034-5288(18)30646-5

2. Tulman ER, Afonso CL, Lu Z, Zsak L, Kutish GF, Rock DL. Genome of lumpy skin disease virus. J Virol. (2001) 75:7122–30. doi: 10.1128/JVI.75.15.7122-7130.2001

3. Tulman ER, Afonso CL, Lu Z, Zsak L, Sur JH, Sandybaev NT, et al. The genomes of sheeppox and goatpox viruses. *J Virol.* (2002) 76:6054–61. doi: 10.1128/jvi.76.12.6054-6061.2002

4. Tuppurainen ES, Pearson CR, Bachanek-Bankowska K, Knowles NJ, Amareen S, Frost L, et al. Characterization of sheep pox virus vaccine for cattle against lumpy skin disease virus. *Antivir Res.* (2014) 109:1–6. doi: 10.1016/j.antiviral.2014.06.009

5. Alemayehu G, Zewde G, Admassu B. Risk assessments of lumpy skin diseases in Borena bull market chain and its implication for livelihoods and international trade. *Trop Anim Health Prod.* (2013) 45:1153–9. doi: 10.1007/s11250-012-0340-9

6. Gari G, Bonnet P, Roger F, Waret-Szkuta A. Epidemiological aspects and financial impact of lumpy skin disease in Ethiopia. *Prev Vet Med.* (2011) 102:274–83. doi: 10.1016/j.prevetmed.2011.07.003

7. Kahsay T, Negash G, Hagos Y, Hadush B. Pre-slaughter, slaughter and postslaughter defects of skins and hides at the Sheba tannery and leather industry, Tigray

### Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This research was supported by the Guangxi Natural Science Foundation (2023GXNSFAA026273), Guangxi key research and development plan (AB24010161), National Natural Science Foundation of China (31360601), and Guangxi Minzu University (No. 2023KJQD23).

### Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

### **Generative AI statement**

The author(s) declare that no Gen AI was used in the creation of this manuscript.

### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

### Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fvets.2025.1622506/ full#supplementary-material

**SUPPLEMENTARY TABLE 1** The details of primer sequences.

region, northern Ethiopia. Onderstepoort J Vet Res. (2015) 82:e1–7. doi: 10.4102/ojvr.v82i1.931

8. Haegeman A, De Leeuw I, Saduakassova M, Van Campe W, Aerts L, Philips W, et al. The importance of quality control of LSDV live attenuated vaccines for its safe application in the field. *Vaccine*. (2021) 9:1019. doi: 10.3390/vaccines9091019

9. Hamdi J, Munyanduki H, Omari Tadlaoui K, El Harrak M, Fassi Fihri O. Capripoxvirus infections in ruminants: a review. *Microorganisms*. (2021) 9:902. doi: 10.3390/microorganisms9050902

10. Tuppurainen ES, Oura CA. Review: lumpy skin disease: an emerging threat to Europe, the Middle East and Asia. *Transbound Emerg Dis.* (2012) 59:40–8. doi: 10.1111/j.1865-1682.2011.01242.x

11. Tran HTT, Truong AD, Dang AK, Ly DV, Nguyen CT, Chu NT, et al. Lumpy skin disease outbreaks in Vietnam, 2020. *Transbound Emerg Dis.* (2021) 68:977–80. doi: 10.1111/tbed.14022

12. Bowden TR, Babiuk SL, Parkyn GR, Copps JS, Boyle DB. Capripoxvirus tissue tropism and shedding: a quantitative study in experimentally infected sheep and goats. *Virology*. (2008) 371:380–93. doi: 10.1016/j.virol.2007.10.002

13. Whittle L, Chapman R, Williamson AL. Lumpy skin disease-an emerging cattle disease in Europe and Asia. *Vaccine*. (2023) 11:578. doi: 10.3390/vaccines11030578

14. Zhu Y, Li Y, Bai B, Fang J, Zhang K, Yin X, et al. Construction of an attenuated goatpox virus AV41 strain by deleting the TK gene and ORF8-18. *Antivir Res.* (2018) 157:111–9. doi: 10.1016/j.antiviral.2018.07.008

15. Bartlett N, Symons JA, Tscharke DC, Smith GL. The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. *J Gen Virol.* (2002) 83:1965–76. doi: 10.1099/0022-1317-83-8-1965

16. Melo-Silva CR, Tscharke DC, Lobigs M, Koskinen A, Müllbacher A, Regner M. Ectromelia virus N1L is essential for virulence but not dissemination in a classical model of mousepox. *Virus Res.* (2017) 228:61–5. doi: 10.1016/j.virusres.2016.11.017

17. Zhang M, Sun Y, Chen W, Bu Z. The 135 gene of Goatpox virus encodes an inhibitor of NF- $\kappa$ B and apoptosis and may serve as an improved insertion site to generate vectored live vaccine. *J Virol.* (2018) 92:e00190-18. doi: 10.1128/JVI.00190-18

18. Yang L, Chen YS, Li S, Zhou Y, Zhang YL, Pei RJ, et al. Immunization of mice with vaccinia virus Tiantan strain yields antibodies cross-reactive with protective antigens of monkeypox virus. *Virol Sin.* (2023) 38:162–4. doi: 10.1016/j.virs.2022.10.004

19. Zhen ZD, Zhang LL, Li Q, Zhu Y, Wang XH, Fu XY, et al. Cross-reactive antibodies against monkeypox virus exist in the population immunized with vaccinia Tian Tan strain in China. *Infect Genet Evol.* (2023) 113:105477. doi: 10.1016/j.meegid.2023.105477

20. Zhao Y, Zhao L, Huang P, Ren J, Zhang P, Tian H, et al. Non-replicating vaccinia virus TianTan strain (NTV) translation arrest of viral late protein synthesis associated with anti-viral host factor SAMD9. *Front Cell Infect Microbiol.* (2020) 10:116. doi: 10.3389/fcimb.2020.00116

21. Jacobs BL, Langland JO, Kibler KV, Denzler KL, White SD, Holechek SA, et al. Vaccinia virus vaccines: past, present and future. *Antivir Res.* (2009) 84:1–13. doi: 10.1016/j.antiviral.2009.06.006

22. Zhang Q, Tian M, Feng Y, Zhao K, Xu J, Liu Y, et al. Genomic sequence and virulence of clonal isolates of vaccinia virus Tiantan, the Chinese smallpox vaccine strain. *PLoS One.* (2013) 8:e60557. doi: 10.1371/journal.pone.0060557

23. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. *Am J Epidemiol.* (1938) 27:493–7. doi: 10.1093/oxfordjournals.aje.a118408

24. Benkert P, Biasini M, Schwede T. Toward the estimation of the absolute quality of individual protein structure models. *Bioinformatics*. (2011) 27:343–50. doi: 10.1093/bioinformatics/btq662

25. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL: homology modelling of protein structures and complexes. *Nucleic Acids Res.* (2018) 46:W296–303. doi: 10.1093/nar/gky427

26. Vandenbussche F, Mathijs E, Philips W, Saduakassova M, De Leeuw I, Sultanov A, et al. Recombinant LSDV strains in Asia: vaccine spillover or natural emergence? *Viruses*. (2022) 14:1429. doi: 10.3390/v14071429

27. Tuppurainen ES, Lubinga JC, Stoltsz WH, Troskie M, Carpenter ST, Coetzer JA, et al. Mechanical transmission of lumpy skin disease virus by *Rhipicephalus appendiculatus* male ticks. *Epidemiol Infect*. (2013) 141:425–30. doi: 10.1017/S0950268812000805

28. Zhu J, Gao X, Li Y, Zhang Z, Xie S, Ren S, et al. Human FAM111A inhibits vaccinia virus replication by degrading viral protein I3 and is antagonized by poxvirus host range factor SPI-1. *Proc Natl Acad Sci USA*. (2023) 120:e2304242120. doi: 10.1073/pnas.2304242120

29. Das I, Basantray I, Mamidi P, Nayak TK, P BM, Chattopadhyay S, et al. Heat shock protein 90 positively regulates chikungunya virus replication by stabilizing viral non-structural protein nsP2 during infection. *PLoS One.* (2014) 9:e100531. doi: 10.1371/journal.pone.0100531

30. Manjunatha Reddy GB, Sumana K, Yogisharadhya R, Mohan HV, Lavanya VK, Chethankumar BH, et al. Structural and sequence analysis of the RPO30 gene of sheeppox and goatpox viruses from India. *Vet Q.* (2024) 44:1–12. doi: 10.1080/01652176.2024.2331524

31. Madhavan A, Venkatesan G, Kumar A, Arya S, Pandey AB. Comparative sequence and structural analysis of the ORF095 gene, a vaccinia virus A4L homolog of capripoxvirus in sheep and goats. *Arch Virol.* (2020) 165:1419–31. doi: 10.1007/s00705-020-04623-5

32. Dashprakash M, Venkatesan G, Kumar A, Sankar M, Arya S, Ramakrishnan MA, et al. Prokaryotic expression, purification and evaluation of goatpox virus ORF117 protein as a diagnostic antigen in indirect ELISA to detect goatpox. *Arch Virol.* (2019) 164:1049–58. doi: 10.1007/s00705-019-04170-8

33. Lei C, Yang J, Hu J, Sun X. On the calculation of TCID50 for quantitation of virus infectivity. *Virol Sin.* (2021) 36:141–4. doi: 10.1007/s12250-020-00230-5

34. Yakubitskiy SN, Kolosova IV, Maksyutov RA, Shchelkunov SN. Attenuation of vaccinia virus. *Acta Nat.* (2015) 7:113–21. doi: 10.32607/20758251-2015-7-4-113-121

35. Izmailian R, Hsao JC, Chung CS, Chen CH, Hsu PW, Liao CL, et al. Integrin  $\beta 1$  mediates vaccinia virus entry through activation of PI3K/Akt signaling. J Virol. (2012) 86:6677–87. doi: 10.1128/JVI.06860-11

36. Soares JA, Leite FG, Andrade LG, Torres AA, De Sousa LP, Barcelos LS, et al. Activation of the PI3K/Akt pathway early during vaccinia and cowpox virus infections is required for both host survival and viral replication. *J Virol.* (2009) 83:6883–99. doi: 10.1128/JVI.00245-09

37. Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-brain barrier: from physiology to disease and Back. *Physiol Rev.* (2019) 99:21–78. doi: 10.1152/physrev.00050.2017

38. Profaci CP, Munji RN, Pulido RS, Daneman R. The blood–brain barrier in health and disease: important unanswered questions. *J Exp Med.* (2020) 217:e20190062. doi: 10.1084/jem.20190062